---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-013563"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:36:15.714574+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PBFT02 delivers superior CSF progranulin with AAV1 vector; interim safety and biomarker data promising

## Summary
- Capsid comparison in NHPs: AAV1 vector achieved superior human PGRN levels in CSF versus AAV5 and AAVhu68 after ICM administration.
- In Grn knockout mice, PBFT02 improved lysosomal histopathology and reduced neuroinflammation across brain regions.
- Interim clinical data from upliFT-D trial: Dose 1 well-tolerated; durable CSF progranulin increases sustained up to 12 months.
- NHP biodistribution showed ICM administration of PBFT02 achieved high gene distribution to cortical and sub-cortical brain regions and spinal cord.

## SEC filing metadata
- accession: 0001558370-24-013563
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837024013563/0001558370-24-013563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837024013563/pasg-20241024x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-013563
- JSON: https://secwatch.observer/filing/0001558370-24-013563.json
- Plain text: https://secwatch.observer/filing/0001558370-24-013563.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.